Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.12 USD | -1.89% | -1.89% | -41.68% |
May. 07 | Transcript : Harvard Bioscience, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $24.5M | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-41.68% | 136M | D | ||
+7.32% | 217B | B | ||
+13.83% | 195B | B- | ||
+20.48% | 144B | B- | ||
+31.33% | 112B | A- | ||
+3.19% | 65.83B | A- | ||
+14.64% | 52.67B | B+ | ||
+2.72% | 49.86B | B+ | ||
-5.88% | 38.18B | A | ||
+0.25% | 35.39B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HBIO Stock
- Ratings Harvard Bioscience, Inc.